United Therapeutics UTHR remains poised to expand Tyvaso’s label in the respiratory disease space. It recently unveiled results from the late-stage TETON-2 study, which showed clinical benefit in ...

For individuals living with COPD, small changes may make a difference. Viatris Inc. and Theravance Biopharma US, Inc. COPD, or chronic obstructive pulmonary disease, is a group of life-changing lung ...

Nebulized amphotericin B does not improve exacerbation-free status at 1 year for patients with bronchopulmonary aspergillosis, though it may delay onset and incidence. Investigators searched PubMed ...

Am J Health Syst Pharm. 2006;63(18):1704-1716. The toxicity of nebulized amphotericin B was evaluated in 29 patients suffering from prolonged neutropenia. [42] Amphotericin B 30 mg was diluted in 3 mL ...

Please provide your email address to receive an email when new articles are posted on . More patients in the ED with hemoptysis saw an end to the condition with nebulized vs. IV tranexamic acid.

Amid the coronavirus disease (COVID-19) pandemic, scientists and health experts race to develop drugs and vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Many ...

Use nebulizer and inhaler for the treatment. Young woman inhaling through inhaler mask lying on the couch and chatting in mobile phone. Closeup front view Researchers conducted subgroup analysis of ...

Napa, CA (October 24, 2007) – Data from two Phase III clinical trials were presented today in Chicago at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians (ACCP), ...

Despite several technological and therapeutic advances over the last two or three decades, bronchopulmonary dysplasia remains a significant cause of morbidity in very low birth weight infants.

For individuals living with COPD, small changes may make a difference. Byline: Viatris Inc. and Theravance Biopharma US, Inc. COPD, or chronic obstructive pulmonary disease, is a group of ...